Cellular-level immunomodulation

Cellular-level immunomodulation describes a therapeutic strategy where living cells, typically Mesenchymal Stem Cells (MSCs), are used to orchestrate a broad immune response rather than hitting a single molecular target. This process is mediated by the secretion of a "secretome" containing cytokines like IL-10 and TGF-β, as well as direct cell-cell contact with host immune cells such as T-lymphocytes and macrophages (Galipeau & Sensébé, 2018, Cell Stem Cell). These interactions lead to the suppression of pro-inflammatory pathways and the promotion of regulatory T-cell populations (Kyurkchiev et al., 2014, World Journal of Stem Cells). Clinically, this mechanism is leveraged in the treatment of Graft-versus-Host Disease (GvHD) and various autoimmune conditions where systemic immune dysregulation is present (Weiss & Dahlke, 2019, Frontiers in Immunology). Because the effect is the result of a complex cellular behavior rather than a discrete protein-ligand interaction, it is frequently classified as an "Unknown" or "Cellular" target in drug development pipelines. The therapeutic efficacy depends on the cells' ability to sense the inflammatory environment and respond dynamically by altering their mediator profile. This multi-faceted approach offers potential advantages in complex diseases that are resistant to single-target biologics. However, the lack of a specific molecular target presents challenges for standardization and potency assay development. Safety concerns include the potential for unwanted differentiation or the promotion of tumor growth in certain contexts. Overall, it represents a paradigm shift from molecular pharmacology to cellular therapeutics.

Other names

Cell-mediated immunomodulationParacrine immunomodulationMesenchymal stem cell-mediated immunomodulationCell-cell contact-mediated immunomodulation

Modulation of the immune system through the secretion of anti-inflammatory mediators and direct cell-cell contact with immune effector cells.